Non-Hodgkin Lymphoma

FDA Approves Idelalisib (Zydelig) for Leukemia and Lymphoma

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for people with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma (another type of non-Hodgkin lymphoma). Learn more here.

FDA Approves Beleodaq (belinostat) for Type of T-cell Lymphoma

The US Food and Drug Administration (FDA) has approved Beleodaq (belinostat) for people with peripheral T-cell lymphoma who did not get better after treatment with other drugs, or whose cancer came back after treatment with other drugs.

Study Shows Experimental Drug Idelalisib Effective Against Chronic Lymphocytic Leukemia

A study of idelalisib finds that this experimental targeted therapy drug may effectively treat chronic lymphocytic leukemia (CLL) patients without the need for chemotherapy.

FDA Approves Ibrutinib for Mantle Cell Lymphoma

The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) to treat some people with mantle cell lymphoma. The drug is intended for patients who have stopped responding to treatment, or whose cancer has come back after treatment.

Drug Shows Promise for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Ibrutinib, a new drug under development, is showing promise as a treatment for mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to new studies.

Study Shows Certain Lymphoma Patients Can Avoid Radiation

Researchers from the National Cancer Institute and Stanford University have found that patients with primary mediastinal B-cell lymphoma can be treated successfully without radiation.

Cancer Can Be Treated During Pregnancy

When a pregnant woman is diagnosed with cancer, her treatment decisions are complicated by concern about how treatment may affect the baby’s health.

Experts See Progress, Hope in Battle Against Childhood Cancers

Survival has improved dramatically for kids with cancer over the past 30 years.